相关实验视频
Updated: Jan 15, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
在克罗恩氏病中Upadacitinib诱导疗法:生物耐药患者的回顾性现实研究
1Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Ave, Wuhan, 430022, China.
乌帕达西替尼 (Upadacitinib) 有效地治疗了活跃的克罗恩病.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乌帕达西替尼 (Upadacitinib) 是一种选择性的简氏激酶1 (JAK1) 抑制剂,在克罗恩病 (CD) 治疗中显示出有前途.
- 在中国,对CD治疗的阿帕达西提尼布的现实数据有限.
- 在中国的CD患者中评估upadacitinib的有效性和安全性至关重要.
研究的目的:
- 评估upadacitinib作为激活克罗恩病的诱导疗法的现实有效性.
- 在中国患者队列中评估upadacitinib的安全性.
- 为了确定治疗对upadacitinib的反应的预测因素.
主要方法:
- 追溯的,单中心的队列研究.
- 包括94名活跃的克罗恩病患者,他们接受了upadacitinib治疗.
- 对临床,内镜和安全结果的评估.
主要成果:
- 在第12周,显著的内镜反应 (50%) 和缓解 (39%).
- 临床反应率高 (53%) 和缓解率高 (43%).
- 有利的生物标志物正常化和可管理的不良事件 (34%),主要是淋巴缺血.
结论:
- 乌帕达西丁 (Upadacitinib) 在中国活跃克罗恩病患者中显示出现实有效性和良好的耐受性.
- 这些发现支持JAK1抑制在治疗CD中的实用性.
- 较低的基线疾病活动得分预测更好的缓解率.
更多相关视频
07:34Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
Published on: December 16, 2021
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...